HTBX - Heat Biologics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Heat Biologics, Inc.

801 Capitola Drive
Suite 12
Durham, NC 27713
United States
919-240-7133
http://www.heatbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees30

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey Alan WolfFounder, Chairman, CEO & Pres834.3kN/A1963
Dr. Jeff T. HutchinsChief Scientific Officer & COO536kN/A1959
Mr. Robert J. JakobsVP of Fin., Sec. & ControllerN/AN/A1955
Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D.Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardN/AN/AN/A
Colonel George E. Peoples Jr., M.D., FACSChief Medical AdvisorN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.

Corporate Governance

Heat Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.